Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731063 | 0.77 | MAPT (0.47) | — | |
| SCHEMBL13730581 | 0.75 | GBA1 (0.41) | SLC6A4GBA1 | |
| SCHEMBL27823143 | 0.71 | PTGS2 (0.44) | NR1H2NR1H3EPAS1PTGS1PTGS2 | |
| SCHEMBL25405123 | 0.69 | EPAS1 (0.37) | NR1H2NR1H3SLC6A4EPAS1PTGS1 | |
| SCHEMBL776672 | 0.68 | PTGS2 (0.45) | PTGS1PTGS2 | |
| Mesdopetam SCHEMBL13732678 | 0.68 | KAT6A (0.40) | GBA1 | |
| Mesdopetam SCHEMBL29438806 | 0.68 | KAT6A (0.40) | GBA1 | |
| Mesdopetam SCHEMBL29438808 | 0.68 | KAT6A (0.40) | GBA1 | |
| SCHEMBL13730672 | 0.67 | EPAS1 (0.38) | NR1H2NR1H3SLC6A4EPAS1PTGS1 | |
| SCHEMBL13731260 | 0.67 | CYP4F2 (0.37) | NR1H2NR1H3EPAS1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4243801-A1 | [2-(3-FLUORO-5-METHANESULFONYLPHENOXY)ETHYL](PROPYL)AMINE (MESDOPETAM) FOR USE IN THE PREVENTION OR REDUCTION OF SENSITIZATION TO A PHARMACEUTICAL DRUG FOR PARKINSON'S DISEASE, IN PARTICULAR L-DOPA INDUCED DYSKINESIAS | Integrative Research Laboratories Sweden AB (SE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022101227-A1 | [2-(3-FLUORO-5-METHANESULFONYLPHENOXY)ETHYL](PROPYL)AMINE (MESDOPETAM) FOR USE IN THE PREVENTION OR REDUCTION OF SENSITIZATION TO A PHARMACEUTICAL DRUG FOR PARKINSON'S DISEASE, IN PARTICULAR L-DOPA INDUCED DYSKINESIAS | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2022-05-19 | — | — | WO | disclosed |